"As the first and exclusive surgical site in Canada to perform this procedure, we will be continuing to shape the future of neurological care and further defining our track record for doing what hasn’t been done," Dr. Kevin Smith, UHN's President & CEO, says of UHN's selection as Canadian site for the CAN-PRIME study, a clinical trial involving the Neuralink implantable device. (Photo: UHN)